Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 351,429 | 279,048 | 239,426 | 215,621 | 228,586 |
| TOTAL | $362,222 | $285,767 | $245,875 | $222,357 | $231,220 |
| Non-Current Assets | |||||
| PPE Net | 2,933 | 2,021 | 1,680 | 1,652 | 1,456 |
| Other Non-Current Assets | 19,281 | 18,993 | 4,995 | 2,652 | 2,466 |
| TOTAL | $22,214 | $21,014 | $6,675 | $4,304 | $3,922 |
| Total Assets | $384,436 | $306,781 | $252,550 | $226,661 | $235,142 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,682 | 3,339 | 2,655 | 7,660 | 3,064 |
| Accrued Expenses | 10,776 | 12,753 | 8,415 | 7,123 | 7,700 |
| TOTAL | $15,458 | $16,547 | $11,525 | $15,453 | $11,648 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 13,994 | 12,811 | 0 | 0 | 0 |
| TOTAL | $13,994 | $12,811 | $N/A | $N/A | $N/A |
| Total Liabilities | $29,452 | $29,358 | $11,525 | $15,453 | $11,648 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 29,584 | 28,536 | 27,543 | 25,757 | 24,035 |
| Common Shares | 3 | 2 | 2 | 2 | 2 |
| Retained earnings | -264,238 | -228,434 | -198,716 | -175,207 | -147,941 |
| TOTAL | $354,984 | $277,423 | $241,025 | $211,208 | $223,494 |
| Total Liabilities And Equity | $384,436 | $306,781 | $252,550 | $226,661 | $235,142 |